ARCHIVES

Oral UFT Equivalent To FULV In Stage II and III Colon Cancer

This article is from The Cancer Letter archive.

Vol. 27 No. 7 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

NCI’s Kramer Named Director, NIH Medical Applications Office.

June 16, 2000

Fisher Address Gap Between Clinicians Investigators, A Threat To Patient Welfare

May 28, 1993

Study Finds No Benefit for Frequent CA125 Testing in Recurrent Ovarian Cancer

June 5, 2009

FDA Designates Zometa For Priority Review.

November 30, 2001

Vasectomy Doesn’t Increase Prostate Cancer Risk

July 26, 2002

Stop Cancer Changes Leaders, Focus, Sends $1.6M To NCI

August 30, 1991